Conference Reports for NATAP

EASL 46th Annual Meeting March 30th - April 3rd 2011 Berlin, Germany Back

TMC435 HCV Protease       TMC435 which has shown in this study in naives be potent with 84% SVR rates and is once daily, and phase 3 it was announced is starting now.   Medivir Announces Positive Phase 2b 48-week (SVR24) Interim Results of TMC435 in Treatment-Naive Patients Chronically Infected With Genotype-1 Hepatitis C Virus - (02/22/11)   EASL: The ASPIRE Trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN/RBV treatment: Week 24 interim analysis - (04/01/11)   Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV - (02/22/11)   Medivir Kicks Off Phase 1a Trial of the Hepatitis C Polymerase Inhibitor TMC649128 - (02/17/11)